Emerging Treatment Options in Inflammatory Bowel Disease

Dear Colleagues,

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, results from a multifactorial interplay of genetic, environmental, microbial, and immunological factors. Despite considerable advances in the understanding of its complex pathogenesis, IBD remains a lifelong, relapsing condition for many individuals, necessitating sustained, multidisciplinary management. Conventional treatments—including aminosalicylates, corticosteroids, immunosuppressants, and anti-TNF agents—have played a central role in clinical care but are often limited by primary non-response, secondary loss of response, or intolerable adverse effects.

Recent therapeutic developments have substantially broadened the available treatment landscape. These include selective biologics targeting IL-12/23 and IL-23 pathways, small molecule therapies such as Janus kinase inhibitors and S1P receptor modulators, and microbiome-based interventions. In parallel, emerging strategies in therapeutic drug monitoring, predictive biomarker integration, and individualized treatment algorithms are helping to tailor and optimize care.

Operative endoscopy represents an innovative and evolving therapeutic approach for the management of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. These chronic conditions, characterized by persistent intestinal inflammation, often necessitate advanced treatment strategies to enhance patient quality of life and minimize the need for invasive surgical interventions. Recent advancements in endoscopic technology have introduced minimally invasive procedures, such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), endoscopic balloon dilation, and endoscopic stent placement, that offer targeted treatment options for IBD patients. These procedures are supported by advanced technologies such as chromoendoscopy, which enhances lesion visibility, and confocal laser endomicroscopy, enabling cellular-level visualization during endoscopy. Additionally, the integration of artificial intelligence is improving diagnostic accuracy and therapeutic planning.

This Special Issue of the Journal of Clinical Medicine invites high-quality submissions from clinicians, researchers, and digestive endoscopists that address current and evolving treatment paradigms in IBD. Topics of interest include optimization of established therapies, real-world treatment outcomes, novel mechanisms of action, emerging drug targets, and strategies for managing refractory disease. Moreover, as digestive endoscopy has progressed beyond its traditional diagnostic role to become an integral component of therapeutic strategies for IBD, contributions on advanced endoscopic interventions for managing complications such as strictures, fistulas, and dysplasia are encouraged.

We especially encourage contributions that highlight personalized approaches, patient stratification models, and the integration of new therapies into routine clinical practice.

By consolidating recent advancements and ongoing challenges, this Special Issue seeks to inform clinical decision-making and catalyze future research toward durable, patient-centered management of IBD.

Prof. Dr. Sandro Ardizzone
Dr. Roberta Maselli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.